From ASH 2025 to the Clinic: Global Perspectives on Evolving BTK Therapies in Relapsed/Refractory CLL

This episode features Matthew S. Davids, MD, MMSc; Nelson Hamerschlak, MD, PhD; and Stephen Stilgenbauer, MD, discussing key conference highlights from the 2025 ASH Annual Meeting, with a focus on emerging BTK-targeted therapies in relapsed/refractory CLL. They share global perspectives on real-world use, sequencing strategies, safety considerations, and how new data may shape future clinical practice.